Amantadine NDC 82804-267

NDC codes

FDA NDC Directory

Product NDC (as listed)82804-267Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82804-0267Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82804-267-20	82804026720	20 TABLET in 1 BOTTLE (82804-267-20)Marketed from Feb 18, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Amantadine
Generic name (nonproprietary): amantadine
Active ingredients: Amantadine hydrochloride — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Proficient Rx LP
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214284
Marketing start: Oct 20, 2020
Listing expires: Dec 31, 2027
Other FDA classes: M2 Protein Inhibitors (Mechanism)
Identifiers: Product ID 82804-267_7aa6bc18-1cee-4b6d-b7c3-0bac6a924eceSPL ID 7aa6bc18-1cee-4b6d-b7c3-0bac6a924eceSPL set ID 7aa6bc18-1cee-4b6d-b7c3-0bac6a924eceRxCUI 849395UNII M6Q1EO9TD0UPC 0382804267200
Pharmacologic class: Influenza A M2 Protein Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482804026720 followed by a unit qualifier and the quantity

Package 82804-0267-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 1, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protec…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214284

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214284
Product	Strength	Form · route	Labeler	Product NDC
Amantadine	Amantadine hydrochloride 100 mg/1	TabletOral	Alembic Pharmaceuticals Inc.	62332-586
Amantadine	Amantadine hydrochloride 100 mg/1	TabletOral	Alembic Pharmaceuticals Limited	46708-586
Amantadine	Amantadine hydrochloride 100 mg/1	TabletOral	Coupler LLC	67046-1531
Amantadine	Amantadine hydrochloride 100 mg/1	TabletOral	NCS HealthCare of KY, LLC dba Vangard Labs	0615-8605